CBDP
Cannabidiphorol · CBDP · Discovered 2019
Learn about CBDP (Cannabidiphorol), the CBD analog with an extended seven-carbon side chain discovered alongside THCP in 2019. Explore its potential enhanced potency, limited research, and relationship to CBD.
Psychoactive
No
Discovered
2019
Effects
3 documented
Benefits
1 studied
Overview
Cannabidiphorol (CBDP) was discovered in 2019 by the same Italian research team that identified THCP, led by Dr. Cinzia Citti. Published in the journal Scientific Reports, the discovery characterized CBDP as a CBD analog featuring an elongated seven-carbon (heptyl) alkyl side chain, compared to CBD's standard five-carbon (pentyl) chain. This mirrors the structural relationship between THCP and THC, where the extended side chain dramatically enhanced CB1 binding affinity.
However, the implications of CBDP's extended side chain are less straightforward than THCP's. While THCP's elongated chain resulted in 33 times greater CB1 binding affinity compared to THC, CBD already has very low CB1 receptor affinity, so enhancing it does not necessarily translate to dramatically different effects. CBD's therapeutic actions are primarily mediated through serotonin receptors, TRP channels, GABA receptors, and indirect endocannabinoid modulation rather than direct cannabinoid receptor binding.
CBDP remains one of the least studied cannabinoids in existence. Beyond the initial 2019 discovery paper, virtually no pharmacological research has been published specifically examining CBDP's biological activity, receptor binding profile, or therapeutic potential. Whether CBDP's extended side chain enhances its activity at CBD's primary therapeutic targets (5-HT1A, TRPV1, PPARgamma, GABA-A) is completely unknown and represents a significant research question. The compound exists in only trace amounts in cannabis and is not commercially available in any consumer product format.
Mechanism of Action
CBDP's mechanism of action is uncharacterized. By analogy with CBD, it may interact with serotonin 5-HT1A receptors, TRPV1 channels, PPARgamma nuclear receptors, GABA-A receptors, and the FAAH enzyme involved in anandamide metabolism. The extended seven-carbon side chain could potentially alter affinity at these targets, either enhancing or reducing activity. Unlike THCP (where extended side chain dramatically enhanced CB1 binding), CBDP's effects are less predictable because CBD's primary mechanisms are not CB1/CB2 dependent. No binding assays, functional studies, or in vivo experiments specifically examining CBDP have been published.
Therapeutic Effects
Potential Benefits
Potential Enhanced CBD-Like Activity
Purely theoretical. If CBDP's extended side chain enhances its affinity for CBD's therapeutic targets (serotonin receptors, TRP channels, PPARs), it could potentially be a more potent version of CBD for conditions like anxiety, inflammation, and epilepsy. However, this is speculative — no research has tested these hypotheses.
Side Effects & Risks
- ⚠No side effects documented due to absence of research
- ⚠Safety profile completely unknown
- ⚠Not available in consumer products
- ⚠Long-term effects unknown
Concentration & Sources
Typical Concentration
Trace amounts in certain cannabis cultivars; not commercially available as an isolated product
Found In
Trace amounts in certain cannabis varieties. First identified in the Italian medical cannabis variety FM2. Not commercially available as an isolated product or in any consumer formulations.
Legal Status
Not specifically regulated. Legal in most jurisdictions as a non-psychoactive, naturally occurring cannabinoid. Not scheduled as a controlled substance.
Research Summary
CBDP research is limited almost entirely to the 2019 discovery paper by Citti et al. The study confirmed CBDP's natural occurrence in cannabis, characterized its molecular structure (including the seven-carbon heptyl side chain), and established its structural relationship to CBD. Beyond this initial characterization, no pharmacological studies have been published. The key unanswered research question is whether CBDP's extended side chain enhances its activity at the receptors responsible for CBD's therapeutic effects. If so, CBDP could represent a more potent, natural alternative to CBD for certain applications. Answering this question will require systematic receptor binding studies, functional assays, and eventually preclinical models — none of which have been conducted as of 2025.
Related Cannabinoids
CBDP FAQ
What is CBDP?
CBDP (cannabidiphorol) is a naturally occurring cannabinoid discovered in 2019 by Italian researchers. It is a CBD analog with an extended seven-carbon alkyl side chain compared to CBD's five-carbon chain — the same structural difference that makes THCP 33 times more potent than THC at CB1 receptors. CBDP is non-psychoactive and found in trace amounts in cannabis. Its pharmacological properties are almost entirely uncharacterized.
Is CBDP more potent than CBD?
It is unknown whether CBDP is more potent than CBD. While CBDP's extended side chain mirrors the modification that makes THCP dramatically more potent than THC, the comparison is not straightforward. CBD's therapeutic effects come primarily from non-cannabinoid receptor targets (serotonin, TRP channels, PPARs), and whether a longer side chain enhances activity at these targets has not been studied. It is possible that CBDP could be more potent, less potent, or similarly potent to CBD depending on the specific receptor or pathway in question.
Is CBDP available to buy?
As of 2025, CBDP is not commercially available as an isolated product. It exists in only trace amounts in natural cannabis, making extraction impractical. No companies currently sell CBDP-specific products, and no synthetic production has been scaled for commercial use. CBDP may be present in negligible quantities in some full-spectrum cannabis extracts.
Is CBDP legal?
CBDP is not specifically regulated in any jurisdiction. As a non-psychoactive, naturally occurring cannabinoid structurally related to CBD, it falls outside controlled substance classifications. CBDP is legal wherever CBD is permitted, though its extreme rarity means regulatory attention has not been directed at it specifically.
Continue Exploring
Disclaimer: Cannabinoid information is provided for educational purposes only. Medical benefits are based on published research and are not intended as medical advice. Individual responses to cannabinoids vary. Always consult a healthcare professional before using cannabis for medical purposes. Legal status information is current as of publication but may change — verify your local laws.